Ginsenoside Rg1 treats chronic heart failure by downregulating ERK1/2 protein phosphorylation

IF 1.5 4区生物学 Q4 CELL BIOLOGY

In Vitro Cellular & Developmental Biology. Animal Pub Date : 2024-09-09 DOI:10.1007/s11626-024-00960-w

Liqi Peng, Shaodong Li, Huzhi Cai, Xueliang Chen, Yanping Tang

{"title":"Ginsenoside Rg1 treats chronic heart failure by downregulating ERK1/2 protein phosphorylation","authors":"Liqi Peng, Shaodong Li, Huzhi Cai, Xueliang Chen, Yanping Tang","doi":"10.1007/s11626-024-00960-w","DOIUrl":null,"url":null,"abstract":"<p>In this study, we investigated the potential therapeutic mechanism of ginsenoside Rg1 (GRg1) in chronic heart failure (CHF), focusing on its regulation of ERK1/2 protein phosphorylation. H9c2 cardiomyocytes and SD rats were divided into the control group, CHF (ADR) group, and CHF+ginsenoside Rg1 group using an isolated cardiomyocyte model and an in vivo CHF rat model induced by adriamycin (ADR). Cell viability, proliferation, apoptosis, and the expression of relevant proteins were measured to assess the effects of GRg1. The results showed that treatment with GRg1 increased cell activity and proliferation, while significantly reducing levels of inflammatory and apoptotic factors compared to the CHF (ADR) group. Moreover, the CHF+ginsenoside Rg1 group exhibited higher levels of Bcl-2 mRNA and protein expression, as well as lower levels of Caspase3 and Bax mRNA and protein expression, compared to the CHF (ADR) group. Notably, the CHF+ginsenoside Rg1 group displayed decreased serum NT-proBNP levels and heart weight/body weight (HW/BW) index. Furthermore, the electrocardiogram of rats in the CHF+ginsenoside Rg1 group resembled that of rats in the control group. Overall, our findings suggested that GRg1 alleviated CHF by inhibiting ERK1/2 protein phosphorylation, thereby inhibiting apoptosis, enhancing cell activity and proliferation, and reducing cardiac inflammatory responses.</p>","PeriodicalId":13340,"journal":{"name":"In Vitro Cellular & Developmental Biology. Animal","volume":"24 1","pages":""},"PeriodicalIF":1.5000,"publicationDate":"2024-09-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"In Vitro Cellular & Developmental Biology. Animal","FirstCategoryId":"99","ListUrlMain":"https://doi.org/10.1007/s11626-024-00960-w","RegionNum":4,"RegionCategory":"生物学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q4","JCRName":"CELL BIOLOGY","Score":null,"Total":0}

引用次数: 0

Abstract

In this study, we investigated the potential therapeutic mechanism of ginsenoside Rg1 (GRg1) in chronic heart failure (CHF), focusing on its regulation of ERK1/2 protein phosphorylation. H9c2 cardiomyocytes and SD rats were divided into the control group, CHF (ADR) group, and CHF+ginsenoside Rg1 group using an isolated cardiomyocyte model and an in vivo CHF rat model induced by adriamycin (ADR). Cell viability, proliferation, apoptosis, and the expression of relevant proteins were measured to assess the effects of GRg1. The results showed that treatment with GRg1 increased cell activity and proliferation, while significantly reducing levels of inflammatory and apoptotic factors compared to the CHF (ADR) group. Moreover, the CHF+ginsenoside Rg1 group exhibited higher levels of Bcl-2 mRNA and protein expression, as well as lower levels of Caspase3 and Bax mRNA and protein expression, compared to the CHF (ADR) group. Notably, the CHF+ginsenoside Rg1 group displayed decreased serum NT-proBNP levels and heart weight/body weight (HW/BW) index. Furthermore, the electrocardiogram of rats in the CHF+ginsenoside Rg1 group resembled that of rats in the control group. Overall, our findings suggested that GRg1 alleviated CHF by inhibiting ERK1/2 protein phosphorylation, thereby inhibiting apoptosis, enhancing cell activity and proliferation, and reducing cardiac inflammatory responses.

Abstract Image

查看原文本刊更多论文

人参皂苷 Rg1 通过下调 ERK1/2 蛋白磷酸化治疗慢性心力衰竭

本研究探讨了人参皂苷 Rg1（GRg1）对慢性心力衰竭（CHF）的潜在治疗机制，重点是其对 ERK1/2 蛋白磷酸化的调节作用。利用离体心肌细胞模型和阿霉素（ADR）诱导的体内CHF大鼠模型，将H9c2心肌细胞和SD大鼠分为对照组、CHF（ADR）组和CHF+人参皂苷Rg1组。通过测量细胞活力、增殖、凋亡和相关蛋白的表达来评估 GRg1 的作用。结果显示，与CHF（ADR）组相比，GRg1能提高细胞活性和增殖，同时显著降低炎症因子和凋亡因子的水平。此外，与 CHF（ADR）组相比，CHF+人参皂苷 Rg1 组的 Bcl-2 mRNA 和蛋白表达水平更高，Caspase3 和 Bax mRNA 和蛋白表达水平更低。值得注意的是，CHF+金森甙 Rg1 组的血清 NT-proBNP 水平和心脏重量/体重（HW/BW）指数均有所下降。此外，CHF+人参皂苷 Rg1 组大鼠的心电图与对照组相似。总之，我们的研究结果表明，GRg1通过抑制ERK1/2蛋白磷酸化，从而抑制细胞凋亡，增强细胞活性和增殖，减轻心脏炎症反应，从而缓解CHF。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

In Vitro Cellular & Developmental Biology. Animal 生物-发育生物学

CiteScore

3.70

自引率

4.80%

发文量

审稿时长

3 months

期刊介绍： In Vitro Cellular & Developmental Biology - Animal is a journal of the Society for In Vitro Biology (SIVB). Original manuscripts reporting results of research in cellular, molecular, and developmental biology that employ or are relevant to organs, tissue, tumors, and cells in vitro will be considered for publication. Topics covered include: Biotechnology; Cell and Tissue Models; Cell Growth/Differentiation/Apoptosis; Cellular Pathology/Virology; Cytokines/Growth Factors/Adhesion Factors; Establishment of Cell Lines; Signal Transduction; Stem Cells; Toxicology/Chemical Carcinogenesis; Product Applications.